REGULATORY
PMDA Announces Ongoing Evaluation of Benambax for Risk of Severe Bradycardia
The Pharmaceuticals and Medical Devices Agency (PMDA) announced risk information on April 4 for five products under risk assessment including Sanofi K.K.’s carinii pneumonia treatment Benambax (pentamidine isetionate) and the first-generation antihistamine drug clemastine fumarate. Pentamidine isetionate is currently being…
To read the full story
REGULATORY
- Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
March 17, 2026
- Gaku Hashimoto to Return as Skipper of LDP Team on Drug Innovation
March 17, 2026
- Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
March 16, 2026
- Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
March 16, 2026
- LDP Urges Action on Drug Supply Risks Linked to Reliance on Specific Countries
March 16, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





